Psychotherapy Drugs for Mental Health, End Notes

  1. “2019-2020 National Survey on Drug Use and Health: Model-Based Prevalence Estimates,” Substance Abuse and Mental Health Services Administration, accessed August 24, 2022, samhsa.gov/data/report/2019-2020-nsduh-state-prevalence-estimates.

  2. “Complete Health Indicator Report of Suicide,” Utah Department of Health, accessed August 24, 2022, https://ibis.health.utah.gov/ibisph-view/indicator/complete_profile/SuicDth.html

  3. “H.C.R. 16 Concurrent Resolution Declaring Mental Health Issues to Be a Public Health Crisis at Utah Higher Education Institutions,” Utah State Legislature, accessed August 24, 2022, https://le.utah.gov/~2017/bills/static/hcr016.html

  4. S. Nassir Ghaemi, “Symptomatic Versus Disease-modifying Effects of Psychiatric Drugs,” Acta Psychiatrica Scandinavica 146, no. 3 (June 2, 2022): 251-57. https://doi.org/10.1111/acps.13459

  5. Ni A. Khin, MD; Yeh-Fong Chen, PhD; Yang Yang, PhD; Peiling Yang, PhD; and Thomas P. Laughren, MD, “Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications,” Journal of Clinical Psychiatry, 72, no. 4 (April 15, 2011): 464-72. https://doi.org/10.4088/JCP.10m06191

  6. Malcolm Lader, “Effectiveness of benzodiazepines: do they work or not?” Expert Review of Neurotherapeutics, no. 8 (2008): 1189-119. https://doi.org/10.1586/14737175.8.8.1189

  7. “FDA requiring Boxed Warning update to improve safe use of benzodiazepines drug class,” U.S. Food and Drug Administration, last accessed August 24, 2022, https://www.fda.gov/media/142368/download

  8. Michael Hengartner, “Methodological Flaws, Conflicts of Interest, and Scientific Fallacies: Implications for the Evaluation of Antidepressants’ Efficacy and Harm,” Frontiers in Psychiatry (2017). https://doi.org/10.3389/fpsyt.2017.00275

  9. Andre F. Carvalho, Manu S. Sharma, Andre R. Brunoni, Eduard Vieta, Giovanni A. Fava, “The Safety, Tolerability, and Risks Associated with the Use of Newer Generation Drugs: A Critical Review of the Literature,” Psychotherapy and Psychosomatics, (2016). 10.1159/000447034
  10. Sean J. Belouin and Jack Henningfield, “Psychedelics: where we are now, why we got here, what we must do,” Neuropharmacology, no. 142 (November 2018): 7-19, https://doi.org/10.1016/j.neuropharm.2018.02.018
  11. Cato M. H. de Vos, Natasha L. Mason, and Kim P.C. Kuypers, “Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics,” Frontiers in Psychiatry (September 2021), https://doi.org/10.3389/fpsyt.2021.724606
  12. “Austria Decriminalizes Psilocybin Mushrooms,” Psychedelic Review, accessed August 24, 2022, https://psychedelicreview.com/event/austria-decriminalizes-psilocybin-mushrooms/
  13. “Psychedelic Drug Laws in Brazil,” Tripsitter, accessed August 24, 2022, https://tripsitter.com/legal/brazil/
  14. Christoph Scheuermann, “The Losers of Prague’s Drug Liberalization,” Spiegel International, March 15, 2013, https://www.spiegel.de/international/europe/the-winners-and-, -of-drug-liberalization-in-the-czech-republic-a-888618.html
  15. Nickieta Sterling, “Protocols in Place for ‘Magic Mushrooms,’” Jamaica Information Service, accessed August 25, 2022, https://jis.gov.jm/protocols-in-place-for-magic-mushrooms/#:~:text=In%20Jamaica%2C%20the%20reality%20is,investors%2C%E2%80%9D%20Minister%20Green%20noted
  16. “Psychedelics Drugs in the Netherlands,” Drug Science, accessed August 25, 2022, https://www.drugscience.org.uk/are-psychedelics-legal-in-the-netherlands/
  17.  “Drug Decriminalization in Portugal: Setting the Record Straight,” Transform Drug Policy Foundation, accessed August 25, 2022, https://transformdrugs.org/blog/drug-decriminalisation-in-portugal-setting-the-record-straights
  18. Organic Law 4/2015 Regarding Protection of Citizen Security, accessed August 25, 2022, https://www.venice.coe.int/webforms/documents/default.aspx?pdffile=CDL-REF(2021)011-e
  19. Melia Robinson, “This South American Country has Decriminalized All Drugs for 40 Years,” Insider, accessed August 25, 2022, https://www.businessinsider.com/uruguay-has-decriminalized-all-drugs-for-40-years-2016-6
  20. “Seattle Legalizes Psychedelics,” Seattle Medium, accessed August 25, 2022, https://seattlemedium.com/seattle-legalizes-psychedelics/
  21. Ann Arbor Decriminalizes Magic Mushrooms, Psychedelic Plants,” Associated Press, accessed August 25, 2022, https://apnews.com/article/ann-arbor-plants-featured-ca-state-wire-mi-state-wire-b0ce69ca0961c150e0f900e8ea4cf432
  22. Nicole Chavez and Ryan Prior, “Denver Becomes the First City to Decriminalize Hallucinogenic Mushrooms,” Central News Network, accessed August 26, 2022, https://www.cnn.com/2019/05/08/us/denver-magic-mushrooms-approved-trnd/index.html
  23. Merrit Kennedy, “Oakland City Council Effectively Decriminalizes Psychedelic Mushrooms,” National Public Radio, accessed on August 26, 2022, https://www.npr.org/2019/06/05/730061916/oakland-city-council-effectively-decriminalizes-psychedelic-mushrooms
  24. Harmeet Kaur, “Santa Cruz Decriminalizes Magic Mushrooms and Other Natural Psychedelics, Making it the Third US City to Take Such a STep,” Central News Network, accessed August 26, 2022, https://www.cnn.com/2020/01/30/us/santa-cruz-mushrooms-psychedelics-trnd/index.html
  25. Deborah Becker, “Cambridge Votes to Decriminalize Psychedelics and All Controlled Substances,” accessed August 26, 2022, https://www.wbur.org/news/2021/02/04/cambridge-votes-to-decriminalize-psychedelics-and-all-controlled-substances
  26. Andrew Beaujon, “Magic Mushrooms are Decriminalized in DC as of Today,” Washingtonian, accessed August 26, 2022, https://www.washingtonian.com/2021/03/15/magic-mushrooms-are-decriminalized-in-dc-as-of-today/
  27. Chris Roberts, “Oregon Legalizes Psilocybin Mushrooms and Decriminalizes All Drugs,” Forbes, accessed August 26, 2022, https://www.forbes.com/sites/chrisroberts/2020/11/04/oregon-legalizes-psilocybin-mushrooms-and-decriminalizes-all-drugs/?sh=6f29dd334b51
  28. “Psilocybin Treatment for Major Depression Effective for Up to a Year for Most Patients, Study Shows,” Johns Hopkins Medicine Newsroom, accessed August 26, 2022, https://www.hopkinsmedicine.org/news/newsroom/news-releases/psilocybin-treatment-for-major-depression-effective-for-up-to-a-year-for-most-patients-study-shows
  29. Roland R. Griffiths, Matthew W. Johnson, Michael A. Carducci, Annie Umbricht, William A. Richards, Brian D. Richards, Mary P Cosimano, and Margaret A. Klinedinst, “Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients with Life-Threatening Cancer: A Randomized Double-Blind Trial,” Journal of Psychopharmacology 30, no. 2 (December 2016): 1181-1197, 10.1177/0269881116675513
  30. Michael P. Bogenschutz, Alyssa A. Forcehimes, Jessica A. Pommy, Claire E. Wilcox, P.C.R> Barbosa, Rick J. Strassman, “Psilocybin-assisted Treatment for Alcohol Dependence, A Proof-of-Concept Study,” Journal of Psychopharmacology 29, 3 (March 2015): 289-299, https://doi.org/10.1177/0269881114565144
  31. Francisco A. Moreno, Christopher B. Wiegand, E. Keolani Taitano, Pedro L. Delgado, “Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients with Obsessive-Compulsive Disorder,” Journal of Clinical Psychiatry 67, no. 11 (November 2006): 1735-40, 10.4088/jcp.v67n1110
  32. oel P. Castellanos, Chris Woolley, Kelly Amanda Bruno, Fadel Zeidan, Adam Halberstadt, Timothy Furnish, “Chronic Pain and Psychedelics: a Review and Proposed Mechanism of Action,” Regional Anesthesia and Pain Medicine 45, no. 7 (July 2020): 486-494, 10.1136/rapm-2020-101273
  33. Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks, Jack E. Henningfield, “The Abuse Potential of Medical Psilocybin According to the 8 Factors of the Controlled Substance Act,” Neuropharmacology, 142 (November 2018): 143-166, https://doi.org/10.1016/j.neuropharm.2018.05.012
  34. Id.
  35. The ratio of the lethal dose to effective dose. The higher the number, the safer a substance. For comparison, the safety ratio of alcohol is 10
  36. Robert S. Gable, “Comparison of Acute Lethal Toxicity of Commonly Abused Psychoactive Substances,” Addiction 99 (February 2004): 686-696, 10.1111/j.1360-0443.2004.00744.x
  37. Christoph Scheuermann, “The Losers of Prague’s Drug Liberalization,” Spiegel International, March 15, 2013, https://www.spiegel.de/international/europe/the-winners-and-, -of-drug-liberalization-in-the-czech-republic-a-888618.html
  38. “Mexico Legalizes Drug Possession,” New York Times, August 21, 2009, https://www.nytimes.com/2009/08/21/world/americas/21mexico.html
  39. “Drug Decriminalization in Portugal: Setting the Record Straight,” Transform Drug Policy Foundation, accessed August 25, 2022, https://transformdrugs.org/blog/drug-decriminalisation-in-portugal-setting-the-record-straights
  40. Organic Law 4/2015 Regarding Protection of Citizen Security, accessed August 25, 2022, https://www.venice.coe.int/webforms/documents/default.aspx?pdffile=CDL-REF(2021)011-e
  41. Melia Robinson, “This South American Country has Decriminalized All Drugs for 40 Years,” Insider, accessed August 25, 2022, https://www.businessinsider.com/uruguay-has-decriminalized-all-drugs-for-40-years-2016-6
  42. Chris Roberts, “Oregon Legalizes Psilocybin Mushrooms and Decriminalizes All Drugs,: Forbes, accessed August 26, 2022, https://www.forbes.com/sites/chrisroberts/2020/11/04/oregon-legalizes-psilocybin-mushrooms-and-decriminalizes-all-drugs/?sh=6f29dd334b51
  43. Juan Jose Fuentes, Francina Fonseca, Matilde Elices, Magi Farre, Marta Torrens, “Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials,” Frontiers in Psychiatry, (January 2020) https://doi.org/10.3389/fpsyt.2019.00943
  44. Joel P. Castellanos, Chris Woolley, Kelly Amanda Bruno, Fadel Zeidan, Adam Halberstadt, Timothy Furnish, “Chronic Pain and Psychedelics: a Review and Proposed Mechanism of Action,” Regional Anesthesia and Pain Medicine 45, no. 7 (July 2020): 486-494, 10.1136/rapm-2020-101273
  45. Friederike Holze, Toya V. Caluori, PAtrick Vizeli, Matthias E. Liechti, “Safety Pharmacology of Acute LSD Administration in Healthy Subjects,” Psychopharmacology 239 (2022): 1893-1905, https://doi.org/10.1007/s00213-021-05978-6
  46. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910402/
  47. Robert S. Gable, “Comparison of Acute Lethal Toxicity of Commonly Abused Psychoactive Substances,” Addiction 99 (February 2004): 686-696, 10.1111/j.1360-0443.2004.00744.x.; see also David E. Nichols, Charles S. Grob, “Is LSD Toxic?” Forensic Science International, 284 (March 018):141-145, 10.1016/j.forsciint.2018.01.006
  48. Roland W. Freudenmann, Florian Oxler, and Sabine Bernschneider-Reif, “The Origin of MDMA (Ecstasy) Revisited: The True Story Reconstructed From the Original Documents,” Addiction (March 2006), 10.1111/j.1360-0443.2006.01511.x
  49. Christoph Scheuermann, “The Losers of Prague’s Drug Liberalization,” Spiegel International, March 15, 2013, https://www.spiegel.de/international/europe/the-winners-and-, -of-drug-liberalization-in-the-czech-republic-a-888618.html
  50. “Mexico Legalizes Drug Possession,” New York Times, August 21, 2009, https://www.nytimes.com/2009/08/21/world/americas/21mexico.html
  51. “Drug Decriminalization in Portugal: Setting the Record Straight,” Transform Drug Policy Foundation, accessed August 25, 2022, https://transformdrugs.org/blog/drug-decriminalisation-in-portugal-setting-the-record-straights
  52. Organic Law 4/2015 Regarding Protection of Citizen Security, accessed August 25, 2022, https://www.venice.coe.int/webforms/documents/default.aspx?pdffile=CDL-REF(2021)011-e
  53. Melia Robinson, “This South American Country has Decriminalized All Drugs for 40 Years,” Insider, accessed August 25, 2022, https://www.businessinsider.com/uruguay-has-decriminalized-all-drugs-for-40-years-2016-6
  54. Chris Roberts, “Oregon Legalizes Psilocybin Mushrooms and Decriminalizes All Drugs,: Forbes, accessed August 26, 2022, https://www.forbes.com/sites/chrisroberts/2020/11/04/oregon-legalizes-psilocybin-mushrooms-and-decriminalizes-all-drugs/?sh=6f29dd334b51
  55. Jennifer M. Mitchell, Michael BogenschutzAlia Lilienstein, Charlotte Harrison, Sarah Kleiman, Kelly Parker-Guilbert, Marcela Ot’alora G., Wael Garas, Casey Paleos, Ingmar Gorman, et al., “MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study,” Nature Medicine 27 (2021):1025-1033, https://doi.org/10.1038/s41591-021-01336-3
  56. Timothy D. Brewerton, Julie B. Wang, Adele Lafrance, Chelsea Pamphlin, Michael Mithoefer, Berra Yazar-Klosinki, Amy Emerson, RickDoblin, “MDMA-Assisted Therapy Significantly Reduces Eating Disorder Symptoms in a Randomized Placebo-Controlled Trial of Adults With Severe PTSD,” Journal of Psychiatric Research 149 (May 2022): 128-135, https://doi.org/10.1016/j.jpsychires.2022.03.008
  57. Christopher R. Nicholas, Julie B. Wnag, Allison Coker, Jennifer M. Mitchell, Sukhpreet S. Klaire, Berra Yazar-Klosinski, Amy Emerson, Randy T. Brown, Rick Doblin, “The Effects of MDMA-Assisted Therapy on Alcohol and Substance Use in a Phase 3 Trial for Treatment of Severe PTSD,” Drug and Alcohol Dependence 233 (April 2022), https://doi.org/10.1016/j.drugalcdep.2022.109356
  58. Michael C. Mithoefer, Mark T. Wagner, Ann T. Mithoefer, Lisa Jerome, Rick Doblin, “The Safety and Efficacy of 3,4-Methylendioxymethamphetamine-Assisted Psychotherapy in Subjects with Chronic, Treatment-Resistant Posttraumatic Stress Disorder: the First Randomized Controlled Pilot Study,”Journal of Psychopharmacology, 25, no. 4 (April 2011): 439-452, 10.1177/0269881110378371
  59. Michael C. Mithoefer, Mark T. Wagner, Ann T. Mithoefer, Lisa Jerome, Scott F. Martin, Berra Yazar-Klosinski, Yvonne Michel, Timothy D. Brewerton, and Rick Doblin, “Durability of Improvement in Post-Traumatic STress Disorder Symptoms and Absence of Harmful Effects or Drug Dependency after 3,4-methelenedioxymethamphetamine-Assisted Psychotherapy: a Prospective Long-Term Follow-Up Study,” Journal of Psychopharmacology 27, no. 1 (January 2013):28-39, 10.1177/0269881112456611
  60. Robert S. Gable, “Comparison of Acute Lethal Toxicity of Commonly Abused Psychoactive Substances,” Addiction 99 (February 2004): 686-696, 10.1111/j.1360-0443.2004.00744.x
  61. Jennifer Ross, “The Battle for the Legality and Legitimacy of Ayahuasca Religions in Brazil,” Department of History seminar paper, Western Oregon University, 2012, https://digitalcommons.wou.edu/cgi/viewcontent.cgi?article=1009&context=his
  62. “Canada,” The International Center for Ethnobotanical Education, Research, and Service, accessed August 29, 2022,  https://www.iceers.org/canada/#:~:text=In%20Canada%2C%20it%20is%20illegal,Controlled%20Drugs%20and%20Substances%20Act
  63. “Czechia Country Drug Report 2019,
     European Monitoring Centre for Drugs and Drug Addiction, https://www.emcdda.europa.eu/system/files/publications/11339/czechia-cdr-2019_0.pdf
  64. Patrick Smith, “Ayahuasca Legal Status by Country,” EntheoNation, accessed August 29, 2022, https://entheonation.com/blog/ayahuasca-legal-country/
  65. “Peru,”  The International Center for Ethnobotanical Education, Research, and Service, accessed August 29, 2022, https://www.iceers.org/peru/#:~:text=Peru%20is%20one%20of%20the,and%20diplomacy%20since%20time%20immemorial
  66. “Drug Decriminalization in Portugal: Setting the Record Straight,” Transform Drug Policy Foundation, accessed August 25, 2022, https://transformdrugs.org/blog/drug-decriminalisation-in-portugal-setting-the-record-straights
  67. Organic Law 4/2015 Regarding Protection of Citizen Security, accessed August 25, 2022, https://www.venice.coe.int/webforms/documents/default.aspx?pdffile=CDL-REF(2021)011-e
  68. Melia Robinson, “This South American Country has Decriminalized All Drugs for 40 Years,” Insider, accessed August 25, 2022, https://www.businessinsider.com/uruguay-has-decriminalized-all-drugs-for-40-years-2016-6
  69.  “Seattle Legalizes Psychedelics,” Seattle Medium, accessed August 25, 2022, https://seattlemedium.com/seattle-legalizes-psychedelics/
  70. “Ann Arbor Decriminalizes Magic Mushrooms, Psychedelic Plants,” Associated Press, accessed August 25, 2022, https://apnews.com/article/ann-arbor-plants-featured-ca-state-wire-mi-state-wire-b0ce69ca0961c150e0f900e8ea4cf432
  71. Merrit Kennedy, “Oakland City Council Effectively Decriminalizes Psychedelic Mushrooms,” National Public Radio, accessed on August 26, 2022, https://www.npr.org/2019/06/05/730061916/oakland-city-council-effectively-decriminalizes-psychedelic-mushrooms
  72. Harmeet Kaur, “Santa Cruz Decriminalizes Magic Mushrooms and Other Natural Psychedelics, Making it the Third US City to Take Such a STep,” Central News Network, accessed August 26, 2022, https://www.cnn.com/2020/01/30/us/santa-cruz-mushrooms-psychedelics-trnd/index.html
  73. Deborah Becker, “Cambridge Votes to Decriminalize Psychedelics and All Controlled Substances,” accessed August 26, 2022, https://www.wbur.org/news/2021/02/04/cambridge-votes-to-decriminalize-psychedelics-and-all-controlled-substances
  74. Andrew Beaujon, “Magic Mushrooms are Decriminalized in DC as of Today,” Washingtonian, accessed August 26, 2022, https://www.washingtonian.com/2021/03/15/magic-mushrooms-are-decriminalized-in-dc-as-of-today/
  75. Chris Roberts, “Oregon Legalizes Psilocybin Mushrooms and Decriminalizes All Drugs,” Forbes, accessed August 26, 2022, https://www.forbes.com/sites/chrisroberts/2020/11/04/oregon-legalizes-psilocybin-mushrooms-and-decriminalizes-all-drugs/?sh=6f29dd334b51
  76. Piera Talin, Emilia Sanabria, “Ayahuasca’s Entwined Efficacy: An Ethnographic Study of Ritual Healing from ‘Addiction,’” International Journal of Drug Policy 44 (June 2017):23-30, 10.1016/j.drugpo.2017.02.017
  77. Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias, Katie C. Andrade, Morgana M. Novaes, Jessica A. Pessoa, Sergio A. Mota-Rolim, Flavia L. Osorio, Rafael Sanches, Rafael G. dos Santos, “Rapid Antidepressant Effects of the Psychedelic Ayahuasca in Treatment-Resistant Depression: a Randomized Placebo-Controlled Trial,” Psychological Medicine 49, no. 4 (March 2019):655-663,  10.1017/S0033291718001356
  78. John H. Halpern, Andrea R. Sherwood, Torsten Passie, Kimberly C. Blackwell, A. James Ruttenber, “Evidence of Health and Safety in America Members of a Religion who Use a Hallucinogenic Sacrament,” Medical Science Monitor 14, no. 8, (August 2008):15-22, https://pubmed.ncbi.nlm.nih.gov/18668010/
  79. Ede Frecska, Petra Bokor, Michael Winkelman, “The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization,” Frontiers in Pharmacology 7, no. 35, (March 2016) 10.3389/fphar.2016.00035
  80. The ratio of the lethal dose to effective dose. The higher the number, the safer a substance. For comparison, the safety ratio of alcohol is 10
  81. Robert S. Gable, “Comparison of Acute Lethal Toxicity of Commonly Abused Psychoactive Substances,” Addiction 99 (February 2004): 686-696, 10.1111/j.1360-0443.2004.00744.x
  82. 21 CFR 1307.3, https://www.ecfr.gov/current/title-21/chapter-II/part-1307/subject-group-ECFR68c82f2ca866120/section-1307.31
  83. Revised Arizona Statute §13-3402, https://law.justia.com/codes/arizona/2015/title-13/section-13-3402
  84. Colorado Revised Statutes, §18-18-418, https://law.justia.com/codes/colorado/2016/title-18/article-18/part-4/section-18-18-418
  85. Idaho Code §37-2732A, https://legislature.idaho.gov/statutesrules/idstat/title37/t37ch27/sect37-2732a/#:~:text=Idaho%20Statutes&text=Use%20of%20peyote%20as%20a,63%2D3622Z%2C%20Idaho%20Code
  86. Minnesota Code §152.02, https://www.revisor.mn.gov/statutes/cite/152.02
  87. Nevada Revised Statutes §453.541, https://www.leg.state.nv.us/nrs/nrs-453.html#NRS453Sec541
  88. New Mexico Code §30-31-6, https://law.justia.com/codes/new-mexico/2011/chapter30/article31/section30-31-6
  89. Chris Roberts, “Oregon Legalizes Psilocybin Mushrooms and Decriminalizes All Drugs,” Forbes, accessed August 26, 2022, https://www.forbes.com/sites/chrisroberts/2020/11/04/oregon-legalizes-psilocybin-mushrooms-and-decriminalizes-all-drugs/?sh=6f29dd334b51
  90. Utah Code §58-37-8(12)
  91. Texas Health and Safety Code §481.111, https://texas.public.law/statutes/tex._health_and_safety_code_section_481.111
  92. Wyoming Statute §35-7-1044, https://law.justia.com/codes/wyoming/2021/title-35/chapter-7/article-10/section-35-7-1044/
  93. Seattle Legalizes Psychedelics,” Seattle Medium, accessed August 25, 2022,  https://seattlemedium.com/seattle-legalizes-psychedelics/
  94. “Ann Arbor Decriminalizes Magic Mushrooms, Psychedelic Plants,” Associated Press, accessed August 25, 2022, https://apnews.com/article/ann-arbor-plants-featured-ca-state-wire-mi-state-wire-b0ce69ca0961c150e0f900e8ea4cf432
  95. Alexander Lekhtman, “Two Years After Oakland’s Psychedelic Decrim, What’s Been the Impact?,” Filter, accessed September 14, 2022, https://filtermag.org/oakland-psychedelic-decriminalization-impact/.Merrit Kennedy, “Oakland City Council Effectively Decriminalizes Psychedelic Mushrooms,” National Public Radio, accessed on August 26, 2022, https://www.npr.org/2019/06/05/730061916/oakland-city-council-effectively-decriminalizes-psychedelic-mushrooms
  96. Harmeet Kaur, “Santa Cruz Decriminalizes Magic Mushrooms and Other Natural Psychedelics, Making it the Third US City to Take Such a Step,” Central News Network, accessed August 26, 2022, https://www.cnn.com/2020/01/30/us/santa-cruz-mushrooms-psychedelics-trnd/index.html
  97. Deborah Becker, “Cambridge Votes to Decriminalize Psychedelics and All Controlled Substances,” accessed August 26, 2022, https://www.wbur.org/news/2021/02/04/cambridge-votes-to-decriminalize-psychedelics-and-all-controlled-substances
  98. Andrew Beaujon, “Magic Mushrooms are Decriminalized in DC as of Today,” Washingtonian, accessed August 26, 2022, https://www.washingtonian.com/2021/03/15/magic-mushrooms-are-decriminalized-in-dc-as-of-today/
  99. “Mescaline (Peyote),” PsychedelicLaw, https://www.psychedeliclaw.ca/mescaline-peyote
  100.  “Czechia Country Drug Report 2019 European Monitoring Centre for Drugs and Drug Addiction, https://www.emcdda.europa.eu/system/files/publications/11339/czechia-cdr-2019_0.pdf
  101. Robin Huang, “Inside a Peyote Pilgrimage,” The New York Times, accessed September 14, 2022, https://www.nytimes.com/2021/07/05/travel/mexico-peyote-pilgrimage.html
  102. Tony Dunnell, “Drugs in Peru: The Laws of Legal and Illegal Possession,” New Peruvian, accessed September 15, 2022, https://www.newperuvian.com/drugs-in-peru-legal-and-illegal/
  103. “Drug Decriminalization in Portugal: Setting the Record Straight,” Transform Drug Policy Foundation, accessed August 25, 2022, https://transformdrugs.org/blog/drug-decriminalisation-in-portugal-setting-the-record-straights
  104.  Organic Law 4/2015 Regarding Protection of Citizen Security, accessed August 25, 2022, https://www.venice.coe.int/webforms/documents/default.aspx?pdffile=CDL-REF(2021)011-e
  105. Decision Number 408, Cabinet of Ministers of Ukraine, May 23, 2012, https://www.nytimes.com/2021/07/05/travel/mexico-peyote-pilgrimage.html
  106. Melia Robinson, “This South American Country has Decriminalized All Drugs for 40 Years,” Insider, accessed August 25, 2022, https://www.businessinsider.com/uruguay-has-decriminalized-all-drugs-for-40-years-2016-6
  107. Malin Uthaug, Alan Davis, Trevor Haas, Dawn Davis, SEan Dolan, Rafael Lancelotta, Christopher Timmermann, Johannes Ramaekers, “The Epidemiology of Mescaline Use: Pattern of Use, Motivations for Consumption, and Perceived Consequences, Benefits, and Acute and Enduring Subjective Effects,” Journal of Psychopharmacology 36, no. 3 (March 2022):309-320, 10.1177/02698811211013583
  108. James Rucker, Jonathan Iliffe, David Nutt, “Psychiatry and the Psychedelic Drugs. Past, Present and Future,” Neuropharmacology 142 (November 2018):200-218, 10.1016/j.neuropharm.2017.12.040. Epub 2017 Dec 25
  109. Uthaug et. al.
  110. GJ Kapadia and MB Fayez, “Peyote Constituents: Chemistry, Biogenesis, and Biological Effects,” Journal of Pharmacological Science 59, no. 12 (1970): 1699-727, 10.1002/jps.2600591202
  111. The ratio of the lethal dose to effective dose. The higher the number, the safer a substance. For comparison, the safety ratio of alcohol is 10
  112. Robert S. Gable, “Comparison of Acute Lethal Toxicity of Commonly Abused Psychoactive Substances,” Addiction 99 (February 2004): 686-696, 10.1111/j.1360-0443.2004.00744.x
  113. Supiro Mandal, Vinod Kumar Sinha, Nishant Goyal, “Efficacy of Ketamine Therapy in the Treatment of Depression,” Indian Journal of Psychology 61, no. 5 (September-October 2019): 480-485, 10.4103/psychiatry.IndianJPsychiatry_484_18
  114. Adriana Feder, Sara Costi, Sarah Rutter, Abigail Collins, Usha Govindarajulu, Manish K. Jha, Sarah R. Horn, MArin Kautz, Morgan Cornique, Katherine A. Collins, et. al., “A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder,” American Journal of Psychiatry (January 2021) https://doi.org/10.1176/appi.ajp.2020.20050596
  115. Ivan Ezquerra-Romano, W. Lawn, E. Krupitsky, C.J.A. Morgan, “Ketamine for the Treatment of Addiction: Evidence and Potential Mechanisms,” Neuropharmacology 142 (November 2018): 72-82, 10.1016/j.neuropharm.2018.01.017
  116. Zimmerman, Andrew. 1991. Treating Autism and Other Developmental Disorders in Children with NMDA Receptor Antagonist. US PAtent Number 4,994,467. Filed May 31, 1989, and issued February 19, 1991
  117. Steven Rosenbaum, Vikas Gupta, Jorge L. Palacios, “Ketamine,” National Library of Medicine, accessed on September 2, 2022, available at https://www.ncbi.nlm.nih.gov/books/NBK470357/
  118. David Feifel, David Dadiomov, Kelly C. Lee, “Safety of Repeated Administration of Parenteral Ketamine for Depression,” Pharmaceuticals 13, no. 7 (July 2020): 151, 10.3390/ph13070151
  119. The ratio of the lethal dose to effective dose. The higher the number, the safer a substance. For comparison, the safety ratio of alcohol is 10
  120. Robert S. Gable, “Comparison of Acute Lethal Toxicity of Commonly Abused Psychoactive Substances,” Addiction 99 (February 2004): 686-696, 10.1111/j.1360-0443.2004.00744.x
  121. M.W. Johnson, W.A. Richards, R.R. Griffiths, “Human Hallucinogen Research: Guidelines for Safety,” Journal of Psychopharmacology 22, no. 6 (August 2008):603-20, 10.1177/0269881108093587
  122. David E. Nichols, “Psychedelics,” Pharmacology Review 68, no. 2 (April 2016): 264-355, 10.1124/pr.115.011478
  123. Jennifer Bronson, Jessica Stroop, Stephanie Zimmerman, Marcus Berzofsky, “Drug Use, Dependence, and Abuse Among State Prisoners and Jail Inmates, 2007-2009,” U.S. Department of Justice, Bureau of Justice Statistics, https://bjs.ojp.gov/content/pub/pdf/dudaspji0709.pdf
  124. Grant M. Jones, Matthew K. Nock, “Psilocybin Use is Associated with Lowered Odds of Crime Arrests in US Adults: A Replication and Extension,” Journal of Psychopharmacology 36, no. 1 (2022):66-73, https://doi.org/10.1177/02698811211058933
  125. P.S. Hendricks, C.B. Clark, M.W. Johnson, Kevin R. Fontaine, Karen L. Cropsey, “Hallucinogen Use Predicts Reduced Recidivism Among Substance-Involved Offenders Under Community Corrections Supervision,” Journal of Psychopharmacology 28, no. 1 (January 2014): 62–66, 10.1177/0269881113513851
  126. Zach Walsh, Peter S. Hendricks, Stephanie Smith, David S. Kosson, Michelle S. Thiessen, Philippe Lucas, Marc T. Swogger, “Hallucinogen Use and Intimate Partner Violence: Prospective Evidence Consistent with Protective Effects among Men with Histories of Problematic Substance Use,” Journal of Psychopharmacology 307, no. 7 (July 2016): 601–607, 10.1177/0269881116642538
  127. P. Vizeli, M. Liechti, “Safety Pharmacology of Acute MDMA Administration in Healthy Subjects,” Journal of Psychopharmacology 31 (2017):576-588, 10.1177/0269881117691569
  128. Vwaire J. Orhurhu, Rishik Vashisht, Lauren E. Claus, Steven P. Cohen, “Ketamine Toxicity,” National Library of Medicine, accessed September 2, 2022, https://www.ncbi.nlm.nih.gov/books/NBK541087/
  129. Joel P. Castellanos, Chris Woolley, Kelly Amanda Bruno, Fadel Zeidan, Adam Halberstadt, Timothy Furnish, “Chronic Pain and Psychedelics: a Review and Proposed Mechanism of Action,” Regional Anesthesia and Pain Medicine 45, no. 7 (July 2020): 486-494, 10.1136/rapm-2020-101273
  130. M.W. Johnson, W.A. Richards, R.R. Griffiths, “Human Hallucinogen Research: Guidelines for Safety,” Journal of Psychopharmacology 22, no. 6 (August 2008):603-20, 10.1177/0269881108093587
  131. Id.
  132. Ericka Dych, “Hitting Highs at Rock Bottom: LSD Treatment for Alcoholism, 1950-1970,” Social History of Medicine 19, no. 2, (August 2006):313-329, https://doi.org/10.1093/shm/hkl039
  133. Kevin Matthews, Shave LeMaster, Sean McAllister, Jamison Brown, Marley Bordovsky, Sara Gael, Chris Hinds, Josh Landy, Beth McCann, Joseph Montoya, “2021 Comprehensive Report,” Psilocybin Mushroom Policy Review Panel, November 9, 2021
  134. Dmitriy Matveychuk, Rejish K. Thomas, Jennifer Swainson, Atul Khullar, Mary-Anne MacKay, Glem B. Baker, Serdar M. Dursun, “Ketamine as an Antidepressant: Overview of its Mechanisms of Action and Potential Predictive Biomarkers,” Therapeutic Advances in Psychopharmacology (May 2020), 10.1177/2045125320916657
  135. “Anesthesia Adverse Events Annual Report,” Utah Department of Health, Center for Health Data and Informatics, available at https://health.utah.gov/wp-content/uploads/2020AnesthesiaAmendment.pdf